(Total Views: 1164)
Posted On: 03/12/2017 1:23:38 PM
Post# of 97
$IMGN flag breakout $3.73
Support on 10 day mvg
Nasdaq GM
Website
Last ten trades
10-K 3/3/17
60% x 100% Strong Buy
Shares Outstanding 87.35M
Float 79.32M
% Held by Insiders 0.36%
% Held by Institutions 91.70%
Shares Short 13.66M
Short Ratio 11.42
Short % of Float 22.92%
Shares Short (prior month) 13.62M
Stock technical analysis
news
and filings
ImmunoGen, Inc., a clinical-stage biotechnology company, develops targeted anticancer therapeutics. The company develops its products using its antibody-drug conjugate (ADC) technology. The companys product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha for the treatment of platinum-resistant ovarian cancer; IMGN529, an ADC that is in Phase 1b/2 clinical trials for B-cell malignancies; coltuximab ravtansine, which is in Phase 2 trials for B-cell malignancies; IMGN779 that is in Phase I clinical trials for the treatment of acute myeloid leukemia (AML); and IMGN632, a preclinical CD123-targeting ADC for the treatment of hematological malignancies, including AML. ImmunoGen, Inc. has collaborations with Roche; Bayer HealthCare AG; Sanofi; Biotest AG; Novartis Institutes for BioMedical Research, Inc.; Eli Lilly and Company; Amgen; Takeda Pharmaceutical Company Limited; Merck; and CytomX Therapeutics, Inc. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.
Support on 10 day mvg
Nasdaq GM
Website
Last ten trades
10-K 3/3/17
60% x 100% Strong Buy
Shares Outstanding 87.35M
Float 79.32M
% Held by Insiders 0.36%
% Held by Institutions 91.70%
Shares Short 13.66M
Short Ratio 11.42
Short % of Float 22.92%
Shares Short (prior month) 13.62M
Stock technical analysis
news
and filings
ImmunoGen, Inc., a clinical-stage biotechnology company, develops targeted anticancer therapeutics. The company develops its products using its antibody-drug conjugate (ADC) technology. The companys product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha for the treatment of platinum-resistant ovarian cancer; IMGN529, an ADC that is in Phase 1b/2 clinical trials for B-cell malignancies; coltuximab ravtansine, which is in Phase 2 trials for B-cell malignancies; IMGN779 that is in Phase I clinical trials for the treatment of acute myeloid leukemia (AML); and IMGN632, a preclinical CD123-targeting ADC for the treatment of hematological malignancies, including AML. ImmunoGen, Inc. has collaborations with Roche; Bayer HealthCare AG; Sanofi; Biotest AG; Novartis Institutes for BioMedical Research, Inc.; Eli Lilly and Company; Amgen; Takeda Pharmaceutical Company Limited; Merck; and CytomX Therapeutics, Inc. ImmunoGen, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.
(0)
(0)
